The Effect of Tasisulam on the CYP2C9-Mediated Metabolism of Tolbutamide: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2011
At a glance
- Drugs Tasisulam; Tolbutamide
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 12 Apr 2011 Status changed from suspended to discontinued, according to ClincalTrials.gov.
- 01 Dec 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 04 Sep 2010 New trial record